In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD TM 2026 International Conference on Alzheimer’s and ...

Shelves filled with green, leafy plants and the owner holding her breath because of possible parking rate hikes on the horizon. Other WRAL Top Stories “That is not sustainable for us,” Anna Grace ...

At the meeting, Piston Bio aligned with the FDA on key elements of the proposed Phase 2 study design, including endpoints, patient population, treatment duration, and dose selection. The agreed Phase ...

More than 200 participants enrolled as company targets topline data by end of 2026 Verdiva Bio has completed enrolment for its phase 2b EVOLVE‑2 clinical study of VRB‑101, a once‑weekly oral GLP‑1 ...

Verdiva Bio Limited (“Verdiva Bio” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, today announced ...

Over 200 participants fully enrolled across 22 sites in the US Trial designed to inform optimal dose and titration schedule of VRB-101 for future clinical development Topline results expected by the ...

TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology ...

Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN ...

The experimental therapy BIO101 may help improve muscle strength in people with spinal muscular atrophy (SMA), according to new research done in laboratory models. “We demonstrated that a daily oral ...

The MarketWatch News Department was not involved in the creation of this content. -- Enara's discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically ...